KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Current Deferred Revenue for 16 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 91.27% year-over-year to $4.8 million, compared with a TTM value of $4.8 million through Dec 2025, down 91.27%, and an annual FY2025 reading of $4.8 million, down 91.27% over the prior year.
  • Current Deferred Revenue was $4.8 million for Q4 2025 at Alnylam Pharmaceuticals, up from $2.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $115.0 million in Q3 2021 and bottomed at $2.5 million in Q3 2025.
  • Average Current Deferred Revenue over 5 years is $63.2 million, with a median of $72.3 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue surged 144.04% in 2023, then plummeted 96.42% in 2025.
  • Year by year, Current Deferred Revenue stood at $88.6 million in 2021, then plummeted by 52.49% to $42.1 million in 2022, then soared by 144.04% to $102.8 million in 2023, then plummeted by 46.01% to $55.5 million in 2024, then plummeted by 91.27% to $4.8 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ALNY at $4.8 million in Q4 2025, $2.5 million in Q3 2025, and $15.1 million in Q2 2025.